Clinical Trials


AbbVie provided data from two Phase III studies in women with uterine fibroids in the first quarter of 2018 and from the associated six-month safety extension during the third quarter of 2018. The ELARIS UF-I and UF-II studies of elagolix were randomized, parallel, double-blind, placebo-controlled clinical trials evaluating the safety, tolerability and efficacy of elagolix alone or in combination with low-dose hormone (add-back) therapy in women with heavy menstrual bleeding associated with uterine fibroids. The studies enrolled approximately 400 patients each for an initial six-month placebo-controlled dosing period.

At the end of the six months of placebo-controlled evaluation, patients were eligible to enter an additional six-month safety extension study. The primary efficacy endpoint of the study was an assessment of the change in menstrual blood loss utilizing the alkaline hematin method comparing baseline to month six. Additional secondary efficacy endpoints were evaluated including the change in fibroid volume and hemoglobin. Bone mineral density was assessed via dual-energy x-ray absorptiometry (DEXA) scan at baseline at the conclusion of dosing and at six months post-dosing.

In August 2019, AbbVie, in cooperation with Neurocrine Biosciences, announced the submission of a New Drug Application (NDA) submission to the FDA for elagolix for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids in women. Elagolix is an investigational treatment for uterine fibroids and is not approved in any country.